PE20010383A1 - NUEVA FORMA CRISTALINA DE CLORHIDRATO DE 6-HIDROXI-3-(4-[2-(PIPERIDIN-1-IL)ETOXI]FENOXI)-2-(4-METOXIFENIL)BENZO[b]TIOFENO - Google Patents
NUEVA FORMA CRISTALINA DE CLORHIDRATO DE 6-HIDROXI-3-(4-[2-(PIPERIDIN-1-IL)ETOXI]FENOXI)-2-(4-METOXIFENIL)BENZO[b]TIOFENOInfo
- Publication number
- PE20010383A1 PE20010383A1 PE2000000758A PE0007582000A PE20010383A1 PE 20010383 A1 PE20010383 A1 PE 20010383A1 PE 2000000758 A PE2000000758 A PE 2000000758A PE 0007582000 A PE0007582000 A PE 0007582000A PE 20010383 A1 PE20010383 A1 PE 20010383A1
- Authority
- PE
- Peru
- Prior art keywords
- piperidin
- thiophene
- methoxyphenyl
- phenoxy
- hydroxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/64—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
Abstract
SE REFIERE AL HIDRATO CRISTALINO DEL CLORHIDRATO DE 6-HIDROXI-3-(4-[2-(PIPERIDIN-1-IL)ETOXI]FENOXI)-2-(4-METOXIFENIL)BENZO[b]TIOFENO (ARZOXIFENO) QUE SE CARACTERIZA POR SU PATRON DE DIFRACCION DE RAYOS X. TAMBIEN SE REFIERE A UNA COMPOSICION QUE COMPRENDE ADEMAS ESTROGENOS, PROGESTAGENOS TAL COMO NORETILNODREL, NORETINDRONA; UN INHIBIDOR DE AROMATASA, UN ANALOGO DE LHRH, UN INHIBIDOR DE ACETIL COLINESTERASA TAL COMO SALICILATO DE FISOSTIGMINA, CLORHIDRATO DE TACRINA, CLORHIDRATO DE DONEPEZILO. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION QUE COMPRENDE CRISTALIZAR CLORHIDRATO DE 6-HIDROXI-3-(4-[2-PIPERIDIN-1-IL)ETOXI]FENOXI)-2-(4-METOXIFENIL)BENZO[b]TIOFENO EN UNA MEZCLA DE AGUA E ISOPROPANOL EN UNA PROPORCION DE 1 Y 9 A 1. EL COMPUESTO ES UN AGONISTA/ANTAGONISTA MIXTO DE ESTROGENOS Y PUEDE SER UTIL PARA REDUCIR LOS NIVELES DE COLESTEROL EN SUERO, INHIBIR LA HIPERLIPIDEMIA, OSTEOPOROSIS, CANCER DE MAMA, CANCER UTERINO, ENDOMETRIOSIS, TRASTORNOS DEL SNC
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14618499P | 1999-07-29 | 1999-07-29 | |
US14764299P | 1999-08-06 | 1999-08-06 | |
US14982099P | 1999-08-19 | 1999-08-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20010383A1 true PE20010383A1 (es) | 2001-04-05 |
Family
ID=27386367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2000000758A PE20010383A1 (es) | 1999-07-29 | 2000-07-31 | NUEVA FORMA CRISTALINA DE CLORHIDRATO DE 6-HIDROXI-3-(4-[2-(PIPERIDIN-1-IL)ETOXI]FENOXI)-2-(4-METOXIFENIL)BENZO[b]TIOFENO |
Country Status (45)
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7122203B2 (en) | 2000-05-08 | 2006-10-17 | Eli Lilly And Company | Stabilized formulations of 6-hydroxy-3-(-4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene and salts thereof |
AU2005200809B2 (en) * | 2000-05-08 | 2006-05-11 | Eli Lilly And Company | Stabilized Formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl) Ethoxy]phenoxy)-2-(4-methoxyphenyl) Benzo[b]thiophene and Salts Thereof |
IL152699A0 (en) * | 2000-05-08 | 2003-06-24 | Lilly Co Eli | STABILIZED FORMULATIONS OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL)ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL) BENZO [b] THIOPHENE AND SALTS THEREOF |
EP1757291A3 (en) * | 2000-05-08 | 2009-07-15 | Eli Lilly & Company | Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-YL)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene and salts thereof |
AU2002214534A1 (en) * | 2000-10-20 | 2002-05-06 | Eli Lilly And Company | A novel crystalline form of 6-hydroxy-3-(4-(2-(piperidin-1-yl)ethoxy)phenoxy)-2- (4-methoxyphenyl)benzo(b)thiophene hydrochloride |
AU2002230409A1 (en) | 2000-11-27 | 2002-06-03 | Eli Lilly And Company | Process for preparing 3-aryl-benzo(b)thiophenes |
WO2006019835A1 (en) * | 2004-07-22 | 2006-02-23 | Eli Lilly And Company | A crystalline variable hydrate of (s)-6-(4-(2-((3-(9h-carbazol-4-yloxy)-2-hydroxypropyl)amino)-2-methylpropyl)phenoxy)-3-pyridinicarbox amide hemisuccinate salt |
CN101087618A (zh) * | 2004-12-23 | 2007-12-12 | 航行药物公司 | 醋酸亮丙瑞林和乙酰胆碱酯酶抑制剂或nmda受体抑制剂在阿尔茨海默氏病治疗中的应用 |
EP1853263A1 (en) * | 2005-02-11 | 2007-11-14 | Eli Lilly And Company | Compositions and methods for treating dyslipidemia |
DE102008057230A1 (de) * | 2008-11-11 | 2010-05-12 | Bayer Schering Pharma Aktiengesellschaft | Synergistische pharmazeutische Kombination mit einem Estrogenrezeptorantagonisten und einem Progestin |
CN113325183B (zh) * | 2021-06-01 | 2022-11-15 | 中国医学科学院北京协和医院 | 一种用于鉴别诊断em/fem的试剂盒 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE207913T1 (de) * | 1995-02-28 | 2001-11-15 | Lilly Co Eli | Benzothiophen-verbindungen, zwischenprodukte, zusammensetzungen und verfahren |
US5510357A (en) * | 1995-02-28 | 1996-04-23 | Eli Lilly And Company | Benzothiophene compounds as anti-estrogenic agents |
ZA982877B (en) * | 1997-04-09 | 1999-10-04 | Lilly Co Eli | Treatment of central nervous system disorders with selective estrogen receptor modulators. |
AU6335600A (en) * | 1999-07-29 | 2001-02-19 | Eli Lilly And Company | A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-metho yphenyl)benzo[b]thiophene hydrochloride |
-
2000
- 2000-07-17 WO PCT/US2000/016332 patent/WO2001009115A2/en active IP Right Grant
- 2000-07-17 AT AT00950222T patent/ATE251151T1/de not_active IP Right Cessation
- 2000-07-17 AU AU63355/00A patent/AU6335500A/en not_active Abandoned
- 2000-07-17 DE DE60005693T patent/DE60005693T2/de not_active Expired - Fee Related
- 2000-07-17 ES ES00950222T patent/ES2208384T3/es not_active Expired - Lifetime
- 2000-07-17 EP EP00950222A patent/EP1204655B1/en not_active Expired - Lifetime
- 2000-07-18 LV LVP-00-95A patent/LV12733B/lv unknown
- 2000-07-24 ID IDP20000630A patent/ID26679A/id unknown
- 2000-07-24 CZ CZ20002717A patent/CZ300356B6/cs not_active IP Right Cessation
- 2000-07-25 HR HR20000502A patent/HRP20000502B1/xx not_active IP Right Cessation
- 2000-07-26 EG EG20000954A patent/EG24196A/xx active
- 2000-07-27 TR TR2000/02205A patent/TR200002205A2/xx unknown
- 2000-07-27 CO CO00056522A patent/CO5180572A1/es not_active Application Discontinuation
- 2000-07-27 NL NL1015822A patent/NL1015822C2/nl not_active IP Right Cessation
- 2000-07-27 IL IL137552A patent/IL137552A/en not_active IP Right Cessation
- 2000-07-28 DK DK200001150A patent/DK176771B1/da not_active IP Right Cessation
- 2000-07-28 HU HU0003005A patent/HUP0003005A2/hu unknown
- 2000-07-28 BE BE2000/0477A patent/BE1013410A3/fr not_active IP Right Cessation
- 2000-07-28 NO NO20003876A patent/NO325594B1/no not_active IP Right Cessation
- 2000-07-28 FR FR0009972A patent/FR2798384B1/fr not_active Expired - Fee Related
- 2000-07-28 KR KR1020000043586A patent/KR100733094B1/ko not_active IP Right Cessation
- 2000-07-28 FI FI20001721A patent/FI20001721A/fi not_active Application Discontinuation
- 2000-07-28 AT AT0132300A patent/AT502317A1/de not_active Application Discontinuation
- 2000-07-28 JP JP2000228949A patent/JP2001048880A/ja active Pending
- 2000-07-28 MD MDA20000161A patent/MD2335G2/ro not_active IP Right Cessation
- 2000-07-28 TW TW089115152A patent/TWI271403B/zh not_active IP Right Cessation
- 2000-07-28 SE SE0002793A patent/SE0002793L/xx unknown
- 2000-07-28 GR GR20000100264A patent/GR20000100264A/el not_active IP Right Cessation
- 2000-07-28 GB GB0018636A patent/GB2352716A/en not_active Withdrawn
- 2000-07-28 CN CNB001222406A patent/CN1138771C/zh not_active Expired - Fee Related
- 2000-07-28 MX MXPA00007462A patent/MXPA00007462A/es active IP Right Grant
- 2000-07-28 LT LT2000075A patent/LT4789B/lt not_active IP Right Cessation
- 2000-07-28 DE DE10036855A patent/DE10036855A1/de not_active Withdrawn
- 2000-07-28 IT IT2000MI001758A patent/IT1318659B1/it active
- 2000-07-28 LU LU90616A patent/LU90616B1/fr active
- 2000-07-28 SG SG200004287A patent/SG90737A1/en unknown
- 2000-07-28 BR BR0003211-5A patent/BR0003211A/pt not_active Application Discontinuation
- 2000-07-28 AU AU48911/00A patent/AU779559B2/en not_active Ceased
- 2000-07-28 SI SI200000173A patent/SI20427B/sl not_active IP Right Cessation
- 2000-07-28 NZ NZ506045A patent/NZ506045A/en unknown
- 2000-07-28 MY MYPI20003448A patent/MY120393A/en unknown
- 2000-07-28 PT PT102501A patent/PT102501A/pt not_active IP Right Cessation
- 2000-07-28 CA CA002314685A patent/CA2314685C/en not_active Expired - Fee Related
- 2000-07-28 PL PL00341748A patent/PL341748A1/xx not_active Application Discontinuation
- 2000-07-28 AR ARP000103929A patent/AR029176A1/es not_active Application Discontinuation
- 2000-07-28 SV SV2000000134A patent/SV2002000134A/es unknown
- 2000-07-31 PE PE2000000758A patent/PE20010383A1/es not_active Application Discontinuation
-
2001
- 2001-08-08 HK HK01105511A patent/HK1034962A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20010383A1 (es) | NUEVA FORMA CRISTALINA DE CLORHIDRATO DE 6-HIDROXI-3-(4-[2-(PIPERIDIN-1-IL)ETOXI]FENOXI)-2-(4-METOXIFENIL)BENZO[b]TIOFENO | |
DE602004016516D1 (de) | Pyrimidin-2,4-dion-derivate als gonadotropin freisetzende hormon-rezeptor-antagonisten | |
PE20060853A1 (es) | 18-metil-19-nor-17-pregn-4-en-21,17-carbolactonas, asi como preparaciones farmaceuticas que las contienen | |
DE69620241D1 (de) | Gonadotropin releasing hormon- antagonisten | |
MX9804850A (es) | Antagonistas de hormona liberadora de gonadotropina. | |
HUP0100120A2 (en) | Pharmaceutical compositions comprising estrogen agonists/antagonists suitable for treating conditions responsive to estrogen | |
IL172834A0 (en) | Pyrimidine-,2,4-dione derivatives and pharmaceutical compositions containing the same | |
FI925652A (fi) | Foerfarande och sammansaettningar foer foerhindrande av befruktning och behandling av benigna gynekologiska stoerningar | |
NO20022966D0 (no) | Drospirenon for hormonerstatningsterapi | |
PE20010385A1 (es) | UNA NUEVA FORMA CRISTALINA DE CLORHIDRATO DE 6-HIDROXI-3-(4-[2-(PIPERIDIN-1-IL)ETOXI]FENOXI)-2-(4-METOXIFENIL)BENZO[b]TIOFENO | |
PE20001563A1 (es) | Antagonistas del receptor de vitronectina | |
BR0114792A (pt) | Composto cristalino, anidro, não solvatado, de cloridreto de 6-hidróxi-3-(-4-[2-piperidin-1-il)-etóxi]-fenóxi)-2-(4-metóx i-fenil)-benzol[b]tiofeno (f-v), formulação farmacêutica, processo para preparar um composto, e uso de um composto | |
PE20010581A1 (es) | Mesoprogestinas (modulares de receptores de progesterona) como componentes de composiciones utilizadas para la terapia de sustitucion hormonal (hrt) | |
CL2004000579A1 (es) | Uso de dienogest para preparar composiciones farmaceuticas destinadas a reducir el cuerpo de la glandula mamaria. | |
PE20020520A1 (es) | Uso de antiprogestinas para la profilaxis y el tratamiento de enfermedades dependientes de hormonas | |
MX9804819A (es) | Antagonistas de hormona liberadora de gonadotropina. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |